Archive

BSH 2017 Debate: Identification and novel management strategies are essential for double hit lymphoma

Double-hit lymphoma has a poor prognosis and the best option for patients could be positive identification and treatment with novel agents, but there are arguments for and against… read more.

BSH 2017: Cancer-related chronic fatique – internet and digital technology solutions

Chronic, cancer-related fatigue (CRF) is associated with a sudden- onset, profound lack of energy that is not relieved by rest. It is different from the fatigue experienced by… read more.

BSH 2017: Plenary debate: Allogeneic transplantation should be considered for selected young patients

Even in the era of novel therapies for newly-diagnosed and relapsed/refractory MM, there is a group of patients for whom the myeloma biology significantly shortens life expectancy. Allogeneic… read more.

BSH 2017: Myeloma XI

Maintenance therapy with lenalidomide can improve PFS in patients with newly-diagnosed MM by almost two years compared with observation alone, in patients of all ages and all risk… read more.

BSH 2017: How I treat molecular high-risk myeloma – what can we do, what should we do?

High-risk multiple myeloma (MM) continues to pose a challenge to haematologists both in terms of diagnostics and therapy. Opening the UK Myeloma Forum at the 2017 BSH annual… read more.

BSH 2017: Are we ready to use minimum residual disease to direct therapy?

Studies show that MM patients who achieve minimal residual disease on treatment have longer PFS and OS than those who do not…

ISH/BSH 2016: DLBCL: controversies and global challenges

Dr Sridhar Chaganti, University Hospital, Birmingham NHS Foundation Trust, UK. by Christine Clark: In general the outcomes of treatment for diffuse large B-cell lymphoma (DLBCL) are good –… read more.

ISH/BSH 2016: Changing treatment paradigms in multiple relapse HL

Professor Karl Peggs, University College, London. by Christine Clark: There are numerous regimens for salvage treatment of Hodgkin lymphoma and all are associated with an overall response rate… read more.

ISH/BSH 2016: Professor John Radford (The University of Manchester) and Dr Graham Collins (Oxford University Hospitals) discuss the key issues to come out of the session on challenging current clinical practices in HL. Also included associated article entitled 'Rethinking risk for better outcomes in ASCT'

Rethinking risk for better outcomes in ASCT by Christine Clark Dr Craig Moskowitz, Memorial Sloan Kettering Cancer Center, NY, USA. Patient populations are changing – before 2010 all… read more.

ISH/BSH 2016: Dr Craig Moskowitz (Memorial Sloan Kettering Cancer Center, NY, USA) and Professor David Linch (University College London Hospital) discuss the role of transplant in HL. Also included an associated article entitled ‘Allogeneic stem cell transplantation: still a role in CLL/lymphoma?’

Allogeneic stem cell transplantation: still a role in CLL/lymphoma? by Christine Clark Professor Peter Dreger, Heidelberg University Hospital, Germany. The goal of allogeneic transplant therapy is to provide… read more.

ISH/BSH 2016: Professor Keith Stewart (Mayo Clinic, USA) discusses current dilemmas in MM, not least of which is how to manage patients with the ever growing number of new agents. He discusses the Mayo Clinic algorithm, whilst Professor Paul G. Richardson (Dana-Farber, USA) discusses the Dana-Farber algorithm for managing MM

ISH/BSH 2016 Abstracts and Posters: Results from the NCRI Myeloma XI trial

Charlotte Pawlyn and John R Jones (both of Institute of Cancer Research, London) and Ruth de Tute, St James’s University Hospital, Leeds. by Maria Dalby: Quadruplet therapy with… read more.